| Diabetes and beta cell function: from mechanisms to evaluation and clinical implications S Cernea, M Dobreanu Biochemia medica 23 (3), 266-280, 2013 | 288 | 2013 |
| Diabetes: insulin resistance and derangements in lipid metabolism. Cure through intervention in fat transport and storage I Raz, R Eldor, S Cernea, E Shafrir Diabetes/metabolism research and reviews 21 (1), 3-14, 2005 | 285 | 2005 |
| Therapy in the early stage: incretins S Cernea, I Raz Diabetes care 34 (Supplement_2), S264-S271, 2011 | 152 | 2011 |
| β-cell protection and therapy for latent autoimmune diabetes in adults S Cernea, R Buzzetti, P Pozzilli Diabetes care 32 (Suppl 2), S246, 2009 | 103 | 2009 |
| An update on DPP-4 inhibitors in the management of type 2 diabetes A Cahn, S Cernea, I Raz Expert opinion on emerging drugs 21 (4), 409-419, 2016 | 73 | 2016 |
| Systemic inflammation and COVID-19 mortality in patients with major noncommunicable diseases: chronic coronary syndromes, diabetes and obesity AL Buicu, S Cernea, I Benedek, CF Buicu, T Benedek Journal of Clinical Medicine 10 (8), 1545, 2021 | 59 | 2021 |
| Pharmacological management of glucose dysregulation in patients treated with second-generation antipsychotics S Cernea, L Dima, CU Correll, P Manu Drugs 80 (17), 1763-1781, 2020 | 57 | 2020 |
| C-peptide response and HLA genotypes in subjects with recent-onset type 1 diabetes after immunotherapy with DiaPep277: an exploratory study R Buzzetti, S Cernea, A Petrone, M Capizzi, M Spoletini, S Zampetti, ... Diabetes 60 (11), 3067-3072, 2011 | 54 | 2011 |
| Comparison of pharmacokinetic and pharmacodynamic properties of single-dose oral insulin spray and subcutaneous insulin injection in healthy subjects using the euglycemic clamp … S Cernea, M Kidron, J Wohlgelernter, P Modi, I Raz Clinical therapeutics 26 (12), 2084-2091, 2004 | 54 | 2004 |
| Serum leptin and leptin resistance correlations with NAFLD in patients with type 2 diabetes S Cernea, AL Roiban, E Both, A Huţanu Diabetes/metabolism research and reviews 34 (8), e3050, 2018 | 52 | 2018 |
| Monitoring of antigen-specific CD8 T cells in patients with type 1 diabetes treated with antiCD3 monoclonal antibodies S Cernea, KC Herold Clinical immunology 134 (2), 121-129, 2010 | 45 | 2010 |
| The role of incretin therapy at different stages of diabetes S Cernea The review of diabetic studies: RDS 8 (3), 323, 2011 | 43 | 2011 |
| New potential treatments for protection of pancreatic B‐cell function in Type 1 diabetes S Cernea, P Pozzilli Diabetic medicine 25 (11), 1259-1267, 2008 | 40 | 2008 |
| Dose-response relationship of oral insulin spray in healthy subjects S Cernea, M Kidron, J Wohlgelernter, P Modi, I Raz Diabetes Care 28 (6), 1353-1357, 2005 | 40 | 2005 |
| Noninjectable methods of insulin administration. S Cernea, I Raz Timely Topics in medicine. Cardiovascular Diseases 10, E29-E29, 2006 | 39 | 2006 |
| Pharmacological management of nonalcoholic fatty liver disease in type 2 diabetes S Cernea, A Cahn, I Raz Expert review of clinical pharmacology 10 (5), 535-547, 2017 | 38 | 2017 |
| Insulin therapy: future perspectives S Cernea, I Raz American journal of therapeutics 27 (1), e121-e132, 2020 | 37 | 2020 |
| Diet and coronary heart disease in diabetes S Cernea, N Hancu, I Raz Acta diabetologica 40, s389-s400, 2003 | 34 | 2003 |
| Management of diabetic neuropathy S Cernea, I Raz Metabolism 123, 154867, 2021 | 33 | 2021 |
| Prevention of type 1 diabetes: today and tomorrow S Cernea, M Dobreanu, I Raz Diabetes/Metabolism Research and Reviews 26 (8), 602-605, 2010 | 32 | 2010 |
avivit cahnVerified email at hadassah.org.il
